Rating- neutral; Pharma sector- Poised for strong growth in Q1FY24
时间:2024-06-17 20:05:12 阅读(143)
We anticipate a positive performance from our pharmaceutical sector coverage in Q1FY24, driven by improved sales in the US market and strong performance across most branded markets. As the cost pressures gradually ease, we expect to see a robust y-o-y Ebitda growth of 22% (excluding BIOS and Mankind). In the hospital segment, we project a relatively stable performance compared to the previous quarter, with occupancy trends gradually returning to pre-Covid levels. For diagnostic companies, we anticipate a slight increase in non-Covid realisations per patient on a quarterly basis, supported by price hikes and higher volumes of non-Covid tests. Our top picks in the pharma sector are Sun Pharma (SUNP), Mankind, and Cipla. Although recent price increases may limit short-term upside, we maintain a positive outlook on APHS, Rainbow, and KIMS in the healthcare services sector.
Pharma: Improved US, healthy branded markets, yoy margin expansion in store
Hospitals: Steady quarter in store We expect a sequentially steady performance for the India-based hospitals, with lower occupancies being offset by higher ARPOB. For hospitals, we forecast a topline growth of 15% y-o-y in Q1FY24. Overall, we expect an Ebitda growth of 20% y-o-y for our hospitals.
Diagnostics: We expect an uptick in B2C sales growth
Regarding the diagnostic firms, we anticipate a slight increase in non-Covid revenue per patient q-o-q, supported by price adjustments and higher volumes of non-Covid tests. We have factored in a y-o-y growth of 8-12% in non-Covid sales for DLPL and METROHL. We expect a decrease in Covid-related sales for both compared to the last quarter. In Q1FY24, we project a 20% q-o-q Ebitda growth rate for DLPL and a 2% q-o-q growth rate for METROHL. The lower growth rate for METROHL is due to the loss of the NACO contract, which accounted for 4-5% of sales, starting from February 2023.
猜你喜欢
- Zomato, Reliance Infrastructure, CSB Bank, REC among 148 stocks that hit 52-week highs; 15 touch 52-week lows
- Gold Price Today, 28 March- Prices gain, dollar softens; regulator focus on banking crisis dims gold’s appeal
- L&T shares climb over 2%; reach 52-week high level in intra-day trade
- Google Pixel 7 Pro hands-on review in PHOTOS- First look at design, cameras, specs, features, and more
- Will Nifty rise or fall below 18,600- See SGX Nifty, FII data, US shares, more before market opens
- Govt releases Rs 2,874 crore to PLI beneficiaries so far- Official
- Gold prices likely to trade sideways to down this week; resistance at Rs 50800, support at 49500 per 10 gram
- Gold prices continue to fall amidst mixed global cues; traders eye US PPI, retail sales data
- Zomato Rating- Hold - Profitability at the cost of growth